Furthermore, HDACi can recover inositol 1,4,5-trisphosphate receptor type 3 (IP3R3) expression and enhance cisplatin sensitivity in SMARCA4/A2-deficent tumor cells [59]. Here, ITPR3 is linked to neoplasm.